3/15/21 - 3/14/23
Mary Brunette, MD (Dartmouth-Hitchcock Clinic; Geisel School of Medicine at Dartmouth College)
Medications development is a high priority program at National Institute on Alcohol Abuse and Alcoholism (NIAAA). Currently, only three medications are approved by the Food and Drug Administration (FDA) for the treatment of alcohol problems. These medications have demonstrated small to moderate effect sizes in clinical trials and do not work for everyone. Thus, the search for new molecular targets and more efficacious pharmacotherapies is critical. The purpose of the current contract is to support clinical research sites as part of a medications development clinical trials network for phase II clinical trials for the treatment of alcohol use disorder.